AVAX Technologies Inc represents a commitment to innovation, excellence, and patient-centric care. With a strong corporate philosophy centered around advancing the field of immuno-oncology, AVAX Technologies Inc aims to provide groundbreaking cancer therapies that revolutionize treatment options. The company places a significant emphasis on research and development, continuously striving to develop cutting-edge technologies and therapeutic solutions. AVAX Technologies Inc is dedicated to improving the lives of cancer patients worldwide, offering hope and pioneering approaches to combat this devastating disease. Through their unwavering dedication to these values, AVAX Technologies Inc continues to make significant contributions to the field of oncology.

AVAX Technologies Inc primarily operates in the United States.

AVAX Technologies Inc has achieved several significant milestones in its journey. The company successfully completed its Phase I clinical trial for its cancer immunotherapy product, AVX-01, demonstrating promising initial results. It also secured a licensing agreement with a prominent pharmaceutical company for the development and commercialization of AVX-01. AVAX Technologies Inc further received Fast Track designation from the FDA, highlighting the potential of their innovative therapies. These achievements showcase the company's commitment to advancing novel cancer treatments and position AVAX Technologies Inc as a key player in the biotechnology industry.

AVAX Technologies Inc is a biotechnology company specializing in the development of innovative cancer immunotherapies. The company was founded in 1990 and is headquartered in Philadelphia, Pennsylvania. With a strong focus on personalized oncology treatments, AVAX Technologies Inc utilizes its proprietary technologies to harness the power of the immune system in fighting cancer. Backed by extensive research and clinical trials, AVAX Technologies Inc has made significant strides in advancing cancer treatments. The company's commitment to improving patient outcomes has garnered attention and recognition in the field of cancer immunotherapy. AVAX Technologies Inc continues to drive innovation and contribute to the fight against cancer.

The main competitors of AVAX Technologies Inc in the market are companies like Biogen Inc, Novartis International AG, and Amgen Inc.

AVAX Technologies Inc is primarily active in the biotechnology industry.

The business model of AVAX Technologies Inc is focused on developing and commercializing targeted immunotherapies for the treatment of cancer. They utilize their proprietary platform technology to develop personalized cancer vaccines that stimulate the patient's immune system to recognize and destroy cancer cells. AVAX Technologies Inc aims to improve patient outcomes by providing innovative and effective immunotherapies. They have a strong commitment to research and development, focusing on advancing their pipeline of cancer vaccines. With their dedication to the field of oncology, AVAX Technologies Inc strives to make a significant impact in the fight against cancer.

AVAX Technologies에 대한 현재 주가 수익 비율을 계산할 수 없습니다.

AVAX Technologies에 대한 현재 KUV는 계산할 수 없습니다.

AVAX Technologies에 대한 AlleAktien 품질 점수는 3/10입니다.

AVAX Technologies에 대한 현재 매출은 계산할 수 없습니다.

AVAX Technologies의 현재 이익을 계산할 수 없습니다.

AVAX Technologies Inc is a US-American company that operates in the biotechnology sector. The company's business model is based on the development and marketing of innovative immunotherapy products. The main product of AVAX Technologies Inc is called O-Vax, a vaccine against ovarian cancer. The vaccine is based on stimulating the immune system using specific antibodies. The goal is to mobilize the body's immune defense against cancer cells and achieve targeted eradication of tumor cells. The O-Vax program is currently in Phase III of clinical development. In addition to the O-Vax program, AVAX Technologies has an innovative portfolio of immunotherapeutic products and technologies. The company has extensive experience in identifying new therapeutic target molecules and developing monoclonal antibodies. These products have great potential, especially in cancer immunotherapy. AVAX Technologies is also involved in the production of high-quality biotherapeutics. The company operates its own production facility in the USA, where bioprocesses are carried out under controlled conditions. This ensures compliance with the strict FDA requirements regarding the purity, stability, and effectiveness of the products. Furthermore, AVAX Technologies is also active in the field of drug clinical development. The company collaborates with universities and research institutes worldwide. The business model of AVAX Technologies is focused on achieving a leading position in the field of immunotherapy. To do so, the company focuses on the development and marketing of innovative products and technologies that have the potential to change the healthcare sector sustainably. To achieve this goal, AVAX Technologies relies on close collaboration with leading scientists and research institutions in the field of immunotherapy. Together, they work on new therapy concepts tailored to meet the needs of patients. AVAX Technologies is a company characterized by its high innovative strength and its consistent focus on developing new therapies. With its products and technologies, the company contributes to improving the lives of people with cancer and other serious diseases.

AVAX Technologies은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

AVAX Technologies의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

AVAX Technologies의 ISIN은 US0534953056입니다.

AVAX Technologies의 WKN은 920934입니다.

AVAX Technologies의 티커는 AVXT입니다.

지난 12개월 동안 AVAX Technologies은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 AVAX Technologies은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

AVAX Technologies의 현재 배당 수익률은 입니다.

AVAX Technologies은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

AVAX Technologies은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

AVAX Technologies은 '건강' 섹터에 속합니다.

AVAX Technologies의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 AVAX Technologies는 0 USD를 배당금으로 지급했습니다.

AVAX Technologies의 배당금은 USD에 지급됩니다.